PET/CT in malignant melanoma: contrast-enhanced CT versus plain low-dose CT. (Q53251672)

12 May 2018

title

PET/CT in malignant melanoma: contrast-enhanced CT versus plain low-dose CT. (English)

1 reference

12 May 2018

author

Christian la Fougère

4

1 reference

12 May 2018

Peter Bartenstein

7

object named as

Peter Bartenstein

1 reference

12 May 2018

Mayo Weiss

8

object named as

Mayo Weiss

1 reference

12 May 2018

author name string

Thomas Pfluger

1

1 reference

12 May 2018

Henriette Ingrid Melzer

2

1 reference

12 May 2018

Vera Schneider

3

1 reference

12 May 2018

Eva Coppenrath

5

1 reference

12 May 2018

Carola Berking

6

1 reference

12 May 2018

publication date

6 January 2011

1 reference

12 May 2018

European Journal of Nuclear Medicine and Molecular Imaging

published in

1 reference

12 May 2018

volume

38

1 reference

12 May 2018

issue

5

1 reference

12 May 2018

page(s)

822-831

1 reference

12 May 2018

Evidence and interdisciplinary consense-based German guidelines: diagnosis and surveillance of melanoma

cites work

1 reference

https://api.crossref.org/works/10.1007/S00259-010-1702-Z

PET diagnostic accuracy: improvement with in-line PET-CT system: initial results

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-010-1702-Z

Accuracy of whole-body dual-modality fluorine-18-2-fluoro-2-deoxy-D-glucose positron emission tomography and computed tomography (FDG-PET/CT) for tumor staging in solid tumors: comparison with CT and PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-010-1702-Z

1999 ICP Distinguished Scientist Award. The history of positron emission tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-010-1702-Z

Clinical use of positron emission tomography in the management of cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-010-1702-Z

Clinical applications of fluorodeoxyglucose--positron emission tomography in the management of malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-010-1702-Z

Primary staging and follow-up of high risk melanoma patients with whole-body 18F-fluorodeoxyglucose positron emission tomography: results of a prospective study of 100 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-010-1702-Z

Meta-analysis of the performance of (18)F-FDG PET in cutaneous melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-010-1702-Z

FDG-PET sensitivity for melanoma lymph node metastases is dependent on tumor volume

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-010-1702-Z

The role of fluorine-18 deoxyglucose positron emission tomography in the management of patients with metastatic melanoma: impact on surgical decision making

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-010-1702-Z

Direct comparison of [18F]FDG PET/CT with PET alone and with side-by-side PET and CT in patients with malignant melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-010-1702-Z

Diagnostic performance of whole body dual modality 18F-FDG PET/CT imaging for N- and M-staging of malignant melanoma: experience with 250 consecutive patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-010-1702-Z

Implications of the 2009 American Joint Committee on Cancer Melanoma Staging and Classification on Dermatologists and Their Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-010-1702-Z

Prospective comparison of the impact on treatment decisions of whole-body magnetic resonance imaging and computed tomography in patients with metastatic malignant melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-010-1702-Z

Cost-effectiveness analysis of FDG PET-CT in the management of pulmonary metastases from malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-010-1702-Z

Limitations of CT during PET/CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-010-1702-Z

Pitfalls and artifacts in 18FDG PET and PET/CT oncologic imaging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-010-1702-Z

False-positive FDG PET uptake--the role of PET/CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-010-1702-Z

Utility of preoperative 18F-FDG PET/CT and brain MRI in melanoma patients with palpable lymph node metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-010-1702-Z

High-risk melanoma: accuracy of FDG PET/CT with added CT morphologic information for detection of metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-010-1702-Z

Diagnostic accuracy of contrast-enhanced FDG-PET/CT in primary staging of cutaneous malignant melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-010-1702-Z

Sentinel lymph node excision and PET-CT in the initial stage of malignant melanoma: a retrospective analysis of 61 patients with malignant melanoma in American Joint Committee on Cancer stages I and II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-010-1702-Z

Adverse reactions to iodinated contrast media

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-010-1702-Z

Design, synthesis, and preliminary in vitro and in vivo evaluation of N-(2-diethylaminoethyl)-4-[18F]fluorobenzamide ([18F]-DAFBA): a novel potential PET probe to image melanoma tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00259-010-1702-Z

Low dose non-enhanced CT versus standard dose contrast-enhanced CT in combined PET/CT protocols for staging and therapy planning in non-small cell lung cancer

21 January 2018

1 reference

12 December 2020

Role of computed tomography in the staging of patients with local-regional metastases of melanoma

1 reference

12 December 2020

Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006.

1 reference

12 December 2020

How much intravenous contrast is needed in FDG-PET/CT?

1 reference

12 December 2020

PET scanning for malignant melanoma and positive sentinel node diagnostics

1 reference

12 December 2020

How much CT do we need for PEt/CT? A radiologist's perspective

1 reference

12 December 2020

Restaging of patients with lymphoma. Comparison of low dose CT (20 mAs) with contrast enhanced diagnostic CT in combined [18F]-FDG PET/CT.

1 reference

12 December 2020

Value of contrast-enhanced multiphase CT in combined PET/CT protocols for oncological imaging

1 reference

12 December 2020

How much CT does PET/CT need?

1 reference

12 December 2020

PET/CT in lymphoma: prospective study of enhanced full-dose PET/CT versus unenhanced low-dose PET/CT.

1 reference

12 December 2020

Non-enhanced CT versus contrast-enhanced CT in integrated PET/CT studies for nodal staging of rectal cancer

1 reference

12 December 2020

Comparative study of two whole-body imaging techniques in the case of melanoma metastases: advantages of multi-contrast MRI examination including a diffusion-weighted sequence in comparison with PET-CT

1 reference

12 December 2020

Is 18F-FDG PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma?

1 reference

12 December 2020

Effect of iodinated contrast media on thyroid function in adults

1 reference

12 December 2020

Radiation exposure of patients undergoing whole-body dual-modality 18F-FDG PET/CT examinations.

1 reference

12 December 2020

To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT.

1 reference

12 December 2020

[Brief guidelines: malignant melanoma of the skin]

1 reference

12 December 2020

A combined PET/CT scanner for clinical oncology.

1 reference

12 December 2020

FLUOR-18-FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY (FDG-PET) IN MALIGNANT MELANOMA: Diagnostic comparison with conventional imaging methods

1 reference

12 December 2020

10.1007/S00259-010-1702-Z

Identifiers

DOI

1 reference

12 May 2018

1 reference

12 May 2018